Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||AZ64 + Irinotecan + Temozolomide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AZ64||Trk Receptor Inhibitor (Pan) 31||AZ64 is a selective TRK inhibitor, which potentially leads to decreased growth of TRK-expressing tumors (PMID: 22623209, PMID: 22948297).|
|Irinotecan||Camptosar||CPT-11|Onivyde||TOPO1 inhibitor 10||Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov).|
|Temozolomide||Temodar||Methazolastone|TMZ||Chemotherapy - Alkylating 16||Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|NTRK2 over exp||neuroblastoma||sensitive||AZ64 + Irinotecan + Temozolomide||Preclinical - Cell line xenograft||Actionable||In a preclinical study, AZ64 in combination with Camptosar (irinotecan) and Temodar (temozolomide) improved event-free survival and reduced tumor growth in neuroblastoma cell line xenograft models over expressing Ntrk2 (TrkB), with increased efficacy over chemotherapy alone (PMID: 22623209).||22623209|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|